Artem Plus

# Artem plus (Artemether/Lumefantrine) ## Overview - **Classification**: Antimalarial, Artemisinin-based Combination Therapy (ACT) - **Mechanism**: Artemether generates free radicals, inhibiting parasite growth. Lumefantrine interferes with hemozoin formation, a critical parasite detoxification pathway. ## Primary Indications 1. **Uncomplicated *P. falciparum* malaria**: Treatment of acute, uncomplicated *Plasmodium falciparum* malaria. 2. **Mixed infections**: Treatment of mixed malarial infections including *P. falciparum*. ## Adult Dosing ### Standard Dosing **Uncomplicated *P. falciparum* malaria** - **Dose**: **80 mg Artemether / 480 mg Lumefantrine** (typically 4 tablets of 20mg/120mg each) - **Frequency**: Twice daily (BID) - **Route**: Oral - **Duration**: 3 days (total 6 doses) - **Special Considerations**: Administer with food or a fatty meal to enhance absorption. ### Dose Adjustments - **Renal Impairment**: No dose adjustment generally needed. Monitor for adverse effects. - **Hepatic Impairment**: No specific dose adjustment for mild-moderate impairment. Use with caution in severe impairment. - **Elderly Patients**: No specific dose adjustment. Use with caution due to potential comorbidities. ## Pediatric Dosing *(Dosages based on tablets containing **20 mg Artemether / 120 mg Lumefantrine**)* ### Infants (5 kg to <15 kg; typically 3 months to 3 years) - **Dose**: **1 tablet (20 mg Artemether / 120 mg Lumefantrine)** - **Frequency**: Twice daily (BID) for 3 days. - **Maximum**: Not applicable (weight-banded). - **Special Notes**: Administer with food or breast milk. Tablets may be crushed and mixed with a small amount of water. ### Children (15 kg to <25 kg; typically 3-8 years) - **Dose**: **2 tablets (40 mg Artemether / 240 mg Lumefantrine)** - **Frequency**: Twice daily (BID) for 3 days. - **Maximum**: Not applicable (weight-banded). ### Children (25 kg to <35 kg; typically 8-12 years) - **Dose**: **3 tablets (60 mg Artemether / 360 mg Lumefantrine)** - **Frequency**: Twice daily (BID) for 3 days. - **Maximum**: Not applicable (weight-banded). ### Adolescents (≥35 kg or 13-18 years) - **Dose**: **4 tablets (80 mg Artemether / 480 mg Lumefantrine)** - **Frequency**: Twice daily (BID) for 3 days. - **Maximum**: Adult dose. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to artemether, lumefantrine, or excipients. - **Absolute**: Severe malaria (parenteral treatment is required). - **Absolute**: Concurrent use with drugs metabolized by CYP2D6 (e.g., flecainide, metoprolol) or drugs that prolong QT interval (e.g., class IA/III antiarrhythmics). - **Absolute**: History of congenital QT prolongation, family history of sudden death, or other clinically relevant cardiac conditions (e.g., bradycardia, severe cardiac failure). - **Absolute**: Uncorrected electrolyte disturbances (hypokalemia, hypomagnesemia). ### Common Adverse Effects - **Very Common (>10%)**: Headache, dizziness, anorexia, nausea, vomiting, abdominal pain, diarrhea, fatigue, arthralgia, myalgia. - **Common (1-10%)**: Palpitations, insomnia, rash, pruritus, uncoordinated movements, paresthesia, abnormal gait, tremor. - **Serious but Rare**: QT prolongation (risk of Torsades de Pointes), hypersensitivity reactions, seizures. ### Key Drug Interactions - **CYP3A4 inducers (e.g., Rifampicin, Carbamazepine, Phenytoin)**: Decreases artemether/lumefantrine levels, reducing efficacy. **Avoid co-administration.** - **CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir)**: May increase artemether/lumefantrine levels, increasing toxicity. **Monitor closely.** - **QT-prolonging drugs (e.g., Amiodarone, Quinidine, Macrolides, Fluoroquinolones)**: Additive QT prolongation risk. **Contraindicated.** - **Mefloquine**: May increase QT prolongation risk if given concurrently or before Artemether/Lumefantrine. **Monitor ECG.** - **Grapefruit juice**: Avoid due to potential CYP3A4 inhibition and increased drug levels. ## Monitoring & Follow-up - **Before Treatment**: Consider baseline ECG and electrolyte levels (K+, Mg2+) if cardiac risk factors are present. - **During Treatment**: Monitor for clinical response (fever resolution, parasitemia clearance) and adverse effects. - **Clinical Signs**: Watch for persistent vomiting (requiring re-dosing), signs of worsening malaria, or symptoms of cardiac arrhythmia (e.g., palpitations, syncope). ## Clinical Pearls - 💡 **Food enhances absorption**: Always administer with food or a fatty meal (e.g., milk, peanut butter) to maximize drug absorption and efficacy. - 💡 **Vomiting protocol**: If vomiting occurs within 1-2 hours of a dose, re-administer the full dose. If vomiting persists, consider parenteral antimalarial therapy. - 💡 **Cardiac safety**: Counsel patients to report any symptoms of heart palpitations, dizziness, or fainting immediately. - 💡 **Complete the course**: Emphasize the importance of completing the entire 3-day course, even if symptoms improve, to prevent treatment failure and resistance. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.